glp-1 compounding crackdown news october 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA proposes a new GLP-1

These findings are significant because they are the first to show that encapsulating an MVM supplement with liposomes can influence the pharmacokinetic (PK) profile of multiple vitamins and minerals present in the supplement, thereby impacting the availability of nutrients

They are not intended for human or veterinary use, consumption, diagnosis, treatment, or therapeutic application

This is the ideal scenario for a research peptide

Their cancellation policy is clean (cancel anytime with no contracts or fees) which is a good sign

So we constructed different vectors with and without transit peptide

BPC-157 TB-500 , ,